Nearly a year and a half ago, we released the Season 2 episode “In Sickness and in Health,” which explored new anti-amyloid therapies for Alzheimer’s disease, lecanemab and donanemab, known commercially as Leqembi and Kisunla. 

After more than three years of lecanemab and nearly two years of donanemab in clinical use, how do patients, caregivers, and clinicians view these treatments today? 

In this episode of The Age of Aging, we revisit the therapies reshaping Alzheimer’s care and hear from those experiencing them firsthand. 

Inside this episode 

Resources available on the episode webpage linked below 

Special thanks this episode to Dave and Evelyn, Justin Clapp, PhD, MPH, Kyra O’Brien, MD, Joanne and Bruce Thomas, Sandy Shulan, and Jason Karlawish, MD. 

The Age of Aging is a Penn Memory Center production hosted by Editorial Director Terrence Casey and Producer Jake Johnson, in partnership with the Penn FTD Center, the Penn Institute on Aging, and Penn’s Alzheimer’s Disease Research Center. Contributors include Dalia Elsaid, Jason Karlawish, Emily Largent, and Alison Lynn. 

The Age of Aging is made possible by generous support from the Michael Naidoff Communications Hub fund. 

Caring for an aging loved one isn’t easy — but you don’t have to do it alone. At Rothkoff Law Group, we guide families across New Jersey and Pennsylvania through every stage of your aging journey. Our team of elder care attorneys, geriatric care coordinators, and public benefits specialists advocate for your loved one’s well-being and your peace of mind. Rothkoff Law Group — your partner in advocacy and senior care planning, every step of the way. Visit RothkoffLaw.com.